Payment overview · 2025
General Payments
$11,968.08
46 reported records · 18 companies
Healthcare provider profile · identity verified
Raja G Devanathan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · HOBART, IN · NPI 1871587220
Verified facts
What the public records show
CMS Open Payments records show Raja G Devanathan, M.D. received $11,968.08 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 93.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nucala, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FASENRA as an associated drug or biological on 40035 records involving 10417 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Fasenra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 876 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $11,145.17 | 93.1% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $199.07 | 1.7% | 15 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $127.28 | 1.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $96.57 | 0.8% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $66.99 | 0.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $42.48 | 0.3% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $39.36 | 0.3% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $37.39 | 0.3% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $33.27 | 0.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $27.79 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.77 | 0.2% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $24.92 | 0.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.96 | 0.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $18.76 | 0.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.37 | 0.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.08 | 0.1% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $14.03 | 0.1% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $13.82 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,720.00 | 5 |
| Food and Beverage | $965.09 | 39 |
| Travel and Lodging | $216.00 | 1 |
| Education | $66.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $11,151.39 | 10 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $202.92 | 6 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $155.02 | 10 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $127.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.05 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $42.48 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| Patient Interface Software Normalized: patient interface software |
Device | Philips North America LLC | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| Amara Cushions Normalized: amara cushions |
Device | Philips North America LLC | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUCALA nucala |
2025 | Nucala | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 876 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FASENRA open payments reported associated product |
CMS Open Payments — General Payments 40035 supporting records · 10417 recipient NPIs · example record 1206131346 |
Fasenra · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
876 | 239 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 876 | 239 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 824 | 294 |
| Prednisone | Prednisone | 365 | 213 |
| Montelukast Sodium | Montelukast Sodium | 359 | 104 |
| Breo Ellipta | Fluticasone/Vilanterol | 236 | 69 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 191 | 48 |
| Cefdinir | Cefdinir | 179 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 66 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 30 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 161 | 47 |
| Roflumilast | Roflumilast | 135 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 53 |
| Ventolin Hfa | Albuterol Sulfate | 108 | 37 |
| Azithromycin | Azithromycin | 102 | 55 |
| Furosemide | Furosemide | 91 | 33 |
| Xolair | Omalizumab | 89 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 76 | 33 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 72 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 70 | 24 |
| Spiriva Respimat | Tiotropium Bromide | 61 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 55 | 11 |
| Nucala | Mepolizumab | 55 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 16 |
| Alprazolam | Alprazolam | 41 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 39 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 37 | suppressed |
| Potassium Chloride | Potassium Chloride | 37 | 16 |
| Azelastine Hcl | Azelastine Hcl | 36 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 27 |
| Dupixent Pen | Dupilumab | 30 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Losartan Potassium | Losartan Potassium | 28 | 11 |
| Theophylline Er | Theophylline Anhydrous | 28 | suppressed |
| Dulera | Mometasone/Formoterol | 27 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Gabapentin | Gabapentin | 25 | 11 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 23 | 14 |
| Carvedilol | Carvedilol | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 12 |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Ambrisentan | Ambrisentan | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 12 |
| Daliresp | Roflumilast | 17 | suppressed |
| Fasenra | Benralizumab | 17 | suppressed |
| Lisinopril | Lisinopril | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 11 | suppressed |
| Rifampin | Rifampin | 11 | suppressed |
| Singulair | Montelukast Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $11,968.08 · 46 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AVYCAZ, Amara Cushions, Arikayce, Brinsupri, DUPIXENT, Da Vinci Surgical System, EMBLAVEO, GLASSIA, Hizentra, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, INSPIRE, NUCALA, OPSUMIT, OPSYNVI, PURIFIED CORTROPHIN GEL, Patient Interface Software, SMARTVEST, TEZSPIRE, TRELEGY ELLIPTA, UPTRAVI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nucala play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error